Allopurinol Use in a New Zealand Population: Prevalence and Adherence

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2014 Jan 7

PMID 24390636

Citations 11

Authors

Simon Horsburgh

Pauline Norris

Gordon Becket

Bruce Arroll

Peter Crampton

Jacqueline Cumming

Shirley Keown

Peter Herbison

Affiliations

Soon will be listed here.

Abstract

Allopurinol is effective for the control of gout and its long-term complications when taken consistently. There is evidence that adherence to allopurinol therapy varies across population groups. This may exacerbate differences in the burden of gout on population groups and needs to be accurately assessed. The aim of this study was to describe the prevalence of allopurinol use in a region of New Zealand using community pharmacy dispensing data and to examine the levels of suboptimal adherence in various population groups. Data from all community pharmacy dispensing databases in a New Zealand region were collected for a year covering 2005/2006 giving a near complete picture of dispensings to area residents. Prevalence of allopurinol use in the region by age, sex, ethnicity and socioeconomic position was calculated. Adherence was assessed using the medication possession ratio (MPR), with a MPR of 0.80 indicative of suboptimal adherence. Multiple logistic regression was used to explore variations in suboptimal adherence across population groups. A total of 953 people received allopurinol in the study year (prevalence 3%). Prevalence was higher in males (6%) than in females (1%) and Māori (5%) than non-Māori (3%). The overall MPR during the study was 0.88, with 161 (22%) of patients using allopurinol having suboptimal adherence. Non-Māori were 54% less likely to have suboptimal allopurinol adherence compared to Māori (95% CI 0.30-0.72, p = 0.001). These findings are consistent with those from other studies nationally and internationally and point to the important role for health professionals in improving patient adherence to an effective gout treatment.

Citing Articles

Lived experience of affordability as a barrier to prescription medicines: A longitudinal qualitative study.

Norris P, Keown S, George M, Symon V, Richards R, Bhawan S Explor Res Clin Soc Pharm. 2025; 17:100571.

PMID: 39968512 PMC: 11833638. DOI: 10.1016/j.rcsop.2025.100571.

Impact of removing prescription co-payments on the use of costly health services: a pragmatic randomised controlled trial.

Norris P, Cousins K, Horsburgh S, Keown S, Churchward M, Samaranayaka A BMC Health Serv Res. 2023; 23(1):31.

PMID: 36641460 PMC: 9839957. DOI: 10.1186/s12913-022-09011-0.

Measuring quality of gout management in residential aged care facilities.

Nguyen A, Lind K, Day R, Ross D, Raban M, Georgiou A Rheumatol Adv Pract. 2022; 6(3):rkac091.

PMID: 36465481 PMC: 9710438. DOI: 10.1093/rap/rkac091.

Māori, pharmacists, and medicines adherence - A mixed methods study exploring indigenous experiences of taking medicines 'as prescribed' and mechanisms of support.

Hikaka J, Parore N, Haua R, Anderson A, Hudson M, McIntosh B Explor Res Clin Soc Pharm. 2022; 7:100175.

PMID: 36106156 PMC: 9465430. DOI: 10.1016/j.rcsop.2022.100175.

Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study.

Hull S, Andersen M, Bengtsson J, Skovgaard N, Backe M, Pedersen M Int J Environ Res Public Health. 2022; 19(12).

PMID: 35742495 PMC: 9223075. DOI: 10.3390/ijerph19127247.

References

Schlesinger N, Dalbeth N, Perez-Ruiz F . Gout--what are the treatment options?. Expert Opin Pharmacother. 2009; 10(8):1319-28. DOI: 10.1517/14656560902950742. View

Mikuls T, Saag K . New insights into gout epidemiology. Curr Opin Rheumatol. 2006; 18(2):199-203. DOI: 10.1097/01.bor.0000209435.89720.7c. View

Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M . Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2012; 72(5):694-700. DOI: 10.1136/annrheumdis-2011-201254. View

Robinson P, Taylor W, Merriman T . Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2013; 42(9):997-1007. DOI: 10.1111/j.1445-5994.2012.02794.x. View

Jatrana S, Crampton P . Primary health care in New Zealand: who has access?. Health Policy. 2009; 93(1):1-10. DOI: 10.1016/j.healthpol.2009.05.006. View

Dalbeth N, House M, Horne A, Te Karu L, Petrie K, McQueen F . The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin Rheumatol. 2012; 32(2):247-51. DOI: 10.1007/s10067-012-2110-5. View

Martini N, Bryant L, Te Karu L, Aho L, Chan R, Miao J . Living with gout in New Zealand: an exploratory study into people's knowledge about the disease and its treatment. J Clin Rheumatol. 2012; 18(3):125-9. DOI: 10.1097/RHU.0b013e31824e1f6f. View

Jackson G, Wright C, Thornley S, Taylor W, Te Karu L, Gow P . Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology (Oxford). 2012; 51(10):1820-4. DOI: 10.1093/rheumatology/kes147. View

Winnard D, Wright C, Taylor W, Jackson G, Te Karu L, Gow P . National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012; 51(5):901-9. DOI: 10.1093/rheumatology/ker361. View

10.

Brook R, Forsythe A, Smeeding J, Edwards N . Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010; 26(12):2813-21. DOI: 10.1185/03007995.2010.533647. View

11.

Harrold L, Andrade S, Briesacher B, Raebel M, Fouayzi H, Yood R . Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009; 11(2):R46. PMC: 2688196. DOI: 10.1186/ar2659. View

12.

Dalbeth N, Petrie K, House M, Chong J, Leung W, Chegudi R . Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken). 2011; 63(11):1605-12. DOI: 10.1002/acr.20570. View

13.

Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Garcia Rodriguez L . Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011; 50(5):973-81. DOI: 10.1093/rheumatology/keq363. View

14.

Harrold L, Mazor K, Velten S, Ockene I, Yood R . Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010; 6(4):263-71. PMC: 3134238. DOI: 10.1177/1742395310378761. View

15.

Horsburgh S, Norris P, Becket G, Crampton P, Arroll B, Cumming J . The Equity in Prescription Medicines Use Study: using community pharmacy databases to study medicines utilisation. J Biomed Inform. 2010; 43(6):982-7. DOI: 10.1016/j.jbi.2010.08.004. View

16.

Kleinman N, Brook R, Patel P, Melkonian A, Brizee T, Smeeding J . The impact of gout on work absence and productivity. Value Health. 2007; 10(4):231-7. DOI: 10.1111/j.1524-4733.2007.00173.x. View

17.

Dunbar J, Dunning E, Dwyer K . Compliance measurement with arthritis regimen. Arthritis Care Res. 1989; 2(3):S8-16. DOI: 10.1002/anr.1790020309. View

18.

Andrade S, Kahler K, Frech F, Chan K . Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006; 15(8):565-74. DOI: 10.1002/pds.1230. View

19.

Reach G . Treatment adherence in patients with gout. Joint Bone Spine. 2011; 78(5):456-9. DOI: 10.1016/j.jbspin.2011.05.010. View

20.

Smith E, Diaz-Torne C, Perez-Ruiz F, March L . Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2011; 24(6):811-27. DOI: 10.1016/j.berh.2010.10.004. View